Patents by Inventor John Zebala

John Zebala has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10130645
    Abstract: There is disclosed is a method of treating disease using compound having formula SX-682 alone or in combination with an antineoplastic agent, microtubule affecting agents, antineoplastic agents, anti-angiogenesis agents, VEGF receptor kinase inhibitors, antibodies against the VEGF receptor, interferon, or radiation.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: November 20, 2018
    Assignee: Syntrix Biosystems, Inc.
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Publication number: 20180296580
    Abstract: What is described is a method for treating cancer in a patient in need of such treatment through the use of a dual CXCR1/2 antagonist by administering a therapeutically effective amount of a dual CXCR1/2 antagonist, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.
    Type: Application
    Filed: June 25, 2018
    Publication date: October 18, 2018
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Patent number: 10046002
    Abstract: What is described is a method for treating cancer in a patient in need of such treatment through the use of an antagonist to CXCR1 and/or CXCR2 receptors by administering a therapeutically effective amount of an antagonist of CXCR1 and/or CXCR2, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: August 14, 2018
    Assignee: SYNTRIX BIOSYSTEMS INC.
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Publication number: 20180177808
    Abstract: What is described is a method for treating cancer in a patient in need of such treatment through the use of an antagonist to CXCR1 and/or CXCR2 receptors by administering a therapeutically effective amount of an antagonist of CXCR1 and/or CXCR2, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.
    Type: Application
    Filed: February 23, 2018
    Publication date: June 28, 2018
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Patent number: 9867828
    Abstract: Embodiments of the present invention provide dosage forms and methods for treating a patient with an inflammatory disorder with a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof, that achieve efficacy without concomitant toxicity. Within certain embodiments, the present invention provides a method for treating an inflammatory disorder in a patient with uninterrupted doses of aminopterin.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: January 16, 2018
    Assignee: Aminopterin LLC
    Inventor: John A. Zebala
  • Publication number: 20170319511
    Abstract: Disclosed herein is a composition for oral administration of O-desmethyltramadol that is effective for overcoming resistance to tramadol in patients.
    Type: Application
    Filed: July 27, 2017
    Publication date: November 9, 2017
    Inventor: John A. Zebala
  • Publication number: 20170319510
    Abstract: There is disclosed a method for treating disorders modulated by at least opiate receptor activity or monoamine activity, including acute and chronic pain, comprising administering a pharmaceutical formulation comprising O-desmethyltramadol. Methods are also provided that are effective for overcoming resistance to tramadol in patients.
    Type: Application
    Filed: July 27, 2017
    Publication date: November 9, 2017
    Inventor: John A. Zebala
  • Patent number: 9808432
    Abstract: There is disclosed a method for treating disorders modulated by at least opiate receptor activity or monoamine activity, including acute and chronic pain, comprising administering a pharmaceutical formulation comprising O-desmethyltramadol. Methods are also provided that are effective for overcoming resistance to tramadol in patients.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: November 7, 2017
    Assignee: Syntrix Biosystems Inc.
    Inventor: John A. Zebala
  • Publication number: 20170281659
    Abstract: There is disclosed is a method of treating disease using compound having formula SX-682 alone or in combination with an antineoplastic agent, microtubule affecting agents, antineoplastic agents, anti-angiogenesis agents, VEGF receptor kinase inhibitors, antibodies against the VEGF receptor, interferon, or radiation.
    Type: Application
    Filed: June 20, 2017
    Publication date: October 5, 2017
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Patent number: 9717701
    Abstract: Disclosed herein is a composition for oral administration of O-desmethyltramadol that is effective for overcoming resistance to tramadol in patients.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: August 1, 2017
    Assignee: Syntrix Biosystems Inc.
    Inventor: John A. Zebala
  • Patent number: 9717700
    Abstract: There is disclosed a method for treating disorders modulated by at least opiate receptor activity or monoamine activity, including acute and chronic pain, comprising administering a pharmaceutical formulation comprising O-desmethyltramadol. Methods are also provided that are effective for overcoming resistance to tramadol in patients.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: August 1, 2017
    Assignee: Syntrix Biosystems Inc.
    Inventor: John A. Zebala
  • Patent number: 9707248
    Abstract: There is disclosed is a method of treating cancer using compound having formula SX-682 alone or in combination with an antineoplastic agent, microtubule affecting agents, antineoplastic agents, anti-angiogenesis agents, VEGF receptor kinase inhibitors, antibodies against the VEGF receptor, interferon, or radiation.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: July 18, 2017
    Assignee: Syntrix Biosystems Inc.
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Publication number: 20170128474
    Abstract: What is described is a method for treating cancer in a patient in need of such treatment through the use of an antagonist to CXCR1 and/or CXCR2 receptors by administering a therapeutically effective amount of an antagonist of CXCR1 and/or CXCR2, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.
    Type: Application
    Filed: November 17, 2016
    Publication date: May 11, 2017
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Publication number: 20170128452
    Abstract: Embodiments of the present invention provide dosage forms and methods for treating a patient with an inflammatory disorder with a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof, that achieve efficacy without concomitant toxicity. Within certain embodiments, the present invention provides a method for treating an inflammatory disorder in a patient with uninterrupted doses of aminopterin.
    Type: Application
    Filed: October 14, 2016
    Publication date: May 11, 2017
    Inventor: John A. Zebala
  • Publication number: 20170014435
    Abstract: There is disclosed is a method of treating cancer using compound having formula SX-682 alone or in combination with an antineoplastic agent, microtubule affecting agents, antineoplastic agents, anti-angiogenesis agents, VEGF receptor kinase inhibitors, antibodies against the VEGF receptor, interferon, or radiation.
    Type: Application
    Filed: September 28, 2016
    Publication date: January 19, 2017
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Patent number: 9480694
    Abstract: There is disclosed is a method of treating a pulmonary disease using a pyrimidinecarboxamide compound, and a pharmaceutical composition suitable for inhalation comprising the pyrimidinecarboxamide compound.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: November 1, 2016
    Assignee: Syntrix Biosystems, Inc.
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Publication number: 20160220514
    Abstract: Disclosed herein is a composition for oral administration of O-desmethyltramadol that is effective for overcoming resistance to tramadol in patients.
    Type: Application
    Filed: April 6, 2016
    Publication date: August 4, 2016
    Inventor: John A. Zebala
  • Publication number: 20160074341
    Abstract: There is disclosed a method for treating disorders modulated by at least opiate receptor activity or monoamine activity, including acute and chronic pain, comprising administering a pharmaceutical formulation comprising O-desmethyltramadol. Methods are also provided that are effective for overcoming resistance to tramadol in patients.
    Type: Application
    Filed: November 23, 2015
    Publication date: March 17, 2016
    Inventor: John A. Zebala
  • Patent number: RE47267
    Abstract: There is disclosed pyridine-and pyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include pyridine-and pyrimidinecarboxamides compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: March 5, 2019
    Assignee: Syntrix Biosystems, Inc.
    Inventors: Dean Y. Maeda, John A Zebala
  • Patent number: RE47415
    Abstract: There is disclosed pyridine- and pyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include pyridine- and pyrimidinecarboxamides compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: June 4, 2019
    Assignee: Syntrix Biosystems, Inc.
    Inventors: Dean Y. Maeda, John A. Zebala